Elsevier

Clinics in Liver Disease

Volume 17, Issue 4, November 2013, Pages 587-607
Clinics in Liver Disease

Acetaminophen-related Hepatotoxicity

https://doi.org/10.1016/j.cld.2013.07.005Get rights and content

Section snippets

Key points

  • Acetaminophen (APAP), a widely available antipyretic and analgesic, is the leading worldwide cause of drug overdose and acute liver failure (ALF).

  • Single overdose ingestion and therapeutic misadventure may cause hepatotoxicity.

  • Several factors, such as concomitant alcohol use or abuse, concurrent medications, genetic factors, and nutritional status, can influence the susceptibility and severity of APAP hepatotoxicity.

  • Early manifestations of APAP hepatotoxicity are nonspecific, but require prompt

Epidemiology

APAP has been a major cause of overdose and overdose-related ALF (∼50% of cases) and death in the United States and in many other countries.3, 4, 5, 6 In the United States, APAP overdose is the leading reason for calls to the Poison Control Centers (>100,000 per year) and accounts annually for more than 56,000 emergency room visits, 2600 hospitalizations, and an approximate 450 deaths caused by ALF.3 In the US ALF Multicenter Prospective Study, APAP accounted for 42% (275 of 662) of ALF cases;

Pharmacology and hepatotoxicity

The therapeutic dose of APAP is 325 to 1000 mg/dose (10–15 mg/kg/dose in children), given every 4 to 6 hours, with a maximum recommended daily dose of 4 g (80 mg/kg in children). Although the US Food and Drug Administration (FDA) Advisory Committee proposed a decrease in the maximum daily dose from 4000 to 3250 mg, this recommendation has not been implemented.10 After oral ingestion, APAP is rapidly absorbed from the gastrointestinal tract with peak concentrations being achieved within

Factors influencing APAP-related hepatotoxicity

The ingested dose of APAP seems to be the most important factor determining the development and severity of APAP hepatotoxicity. In addition, the pattern of use and various factors (eg, age, concurrent use of alcohol and certain medications, genetic factors, pre-existing liver disease, and nutritional status) can also influence the susceptibility to APAP hepatotoxicity through several mechanisms including decreased capacity for glucuronidation or sulfation, excessive CYP activity, and depletion

Clinical manifestations

Early recognition of APAP overdose is likely to prevent subsequent morbidity and mortality. The early manifestations of APAP overdose are frequent, mild, and nonspecific, and include nausea, vomiting, malaise, and abdominal pain. In general, these symptoms do not reliably predict subsequent hepatotoxicity. However, a study of 291 patients suggested that an increase in episodes of vomiting at first presentation seems to be a risk marker of subsequent hepatotoxicity.54 The clinical course of APAP

General approach and diagnostic tools

General approach promptly begins with careful history taking and physical examination. The precise time and amount of APAP intake, and 4-hour APAP level, or as soon thereafter as feasible, should be obtained. Other tests, such as hepatic biochemical tests, creatinine, and electrolytes, may also be useful, particularly in patients with repeated overdoses and those who present more than 8 hours after ingestion. Investigations for possible coingested substances and other causes of hepatitis may be

Gastrointestinal Decontamination

Activated charcoal is effective at limiting the absorption of APAP when given within 4 hours after overdose and is recommended in all patients who present early after APAP ingestion, unless there are contraindications (eg, unsecured airway or gastrointestinal tract injury).94, 95, 96, 97 Patients who present 4 hours after ingestion are unlikely to benefit from activated charcoal, except in those who ingested extended-release APAP preparations or coingested drugs that delayed gastric emptying

First page preview

First page preview
Click to open first page preview

References (123)

  • M.M. Rumore et al.

    Influence of age-dependent pharmacokinetics and metabolism on acetaminophen hepatotoxicity

    J Pharm Sci

    (1992)
  • V.F. Price et al.

    Mechanisms of fasting-induced potentiation of acetaminophen hepatotoxicity in the rat

    Biochem Pharmacol

    (1987)
  • N. Chandok et al.

    Pain management in the cirrhotic patient: the clinical challenge

    Mayo Clin Proc

    (2010)
  • P.R. McElhatton et al.

    Paracetamol overdose in pregnancy analysis of the outcomes of 300 cases referred to the Teratology Information Service

    Reprod Toxicol

    (1997)
  • A.J. Singer et al.

    The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction

    Ann Emerg Med

    (1995)
  • A.J. Makin et al.

    A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993)

    Gastroenterology

    (1995)
  • J.G. O'Grady et al.

    Early indicators of prognosis in fulminant hepatic failure

    Gastroenterology

    (1989)
  • T.J. Davern et al.

    Measurement of serum acetaminophen-protein adducts in patients with acute liver failure

    Gastroenterology

    (2006)
  • H.A. Spiller et al.

    A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose

    Ann Emerg Med

    (1994)
  • H.A. Spiller et al.

    Efficacy of activated charcoal administered more than four hours after acetaminophen overdose

    J Emerg Med

    (2006)
  • J.H. Lin et al.

    Sulfate depletion after acetaminophen administration and replenishment by infusion of sodium sulfate or N-acetylcysteine in rats

    Biochem Pharmacol

    (1981)
  • D.K. Wysowski et al.

    Trends in outpatient prescription drug use and related costs in the US: 1998-2003

    Pharmacoeconomics

    (2006)
  • W.M. Lee

    Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure

    Hepatology

    (2004)
  • G. Ostapowicz et al.

    Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States

    Ann Intern Med

    (2002)
  • O.T. Ayonrinde et al.

    Paracetamol overdose and hepatotoxicity at a regional Australian hospital: a 4-year experience

    Intern Med J

    (2005)
  • S.C. Cooper et al.

    Outcomes of liver transplantation for paracetamol (acetaminophen)-induced hepatic failure

    Liver Transpl

    (2009)
  • K.R. Reddy et al.

    Liver transplantation for acute liver failure: results from the NIH Acute Liver Failure Study Group

    Hepatology

    (2012)
  • A.M. Larson et al.

    Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study

    Hepatology

    (2005)
  • E.P. Krenzelok

    The FDA Acetaminophen Advisory Committee Meeting: what is the future of acetaminophen in the United States? The perspective of a committee member

    Clin Toxicol (Phila)

    (2009)
  • J.A. Forrest et al.

    Clinical pharmacokinetics of paracetamol

    Clin Pharmacokinet

    (1982)
  • D.R. Douglas et al.

    A pharmacokinetic comparison of acetaminophen products (Tylenol Extended Relief vs regular Tylenol)

    Acad Emerg Med

    (1996)
  • F.V. Schiodt et al.

    The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage

    Clin Pharmacol Ther

    (2002)
  • G.G. Graham et al.

    Tolerability of paracetamol

    Drug Saf

    (2005)
  • J.R. Mitchell et al.

    Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione

    J Pharmacol Exp Ther

    (1973)
  • T.R. Knight et al.

    Role of lipid peroxidation as a mechanism of liver injury after acetaminophen overdose in mice

    Toxicol Sci

    (2003)
  • M.R. McGill et al.

    The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation

    J Clin Invest

    (2012)
  • H. Jaeschke et al.

    Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity

    Liver Int

    (2012)
  • R.C. Dart et al.

    Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management

    Clin Toxicol (Phila)

    (2006)
  • A.R. Temple et al.

    Aminotransferase activities in healthy subjects receiving three-day dosing of 4, 6, or 8 grams per day of acetaminophen

    Clin Toxicol (Phila)

    (2007)
  • P.B. Watkins et al.

    Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial

    JAMA

    (2006)
  • W.M. Lee

    Drug-induced hepatotoxicity

    N Engl J Med

    (2003)
  • W.S. Waring et al.

    Acute ethanol coingestion confers a lower risk of hepatotoxicity after deliberate acetaminophen overdose

    Acad Emerg Med

    (2008)
  • B.H. Lauterburg et al.

    Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity

    Gut

    (1988)
  • P. Zhao et al.

    Effects of ethanol dose and ethanol withdrawal on rat liver mitochondrial glutathione: implication of potentiated acetaminophen toxicity in alcoholics

    Drug Metab Dispos

    (2002)
  • K.E. Thummel et al.

    Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults

    Clin Pharmacol Ther

    (2000)
  • F.V. Schiodt et al.

    Acetaminophen toxicity in an urban county hospital

    N Engl J Med

    (1997)
  • R.C. Dart et al.

    Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review

    Am J Ther

    (2000)
  • E.K. Kuffner et al.

    Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial

    Arch Intern Med

    (2001)
  • B.H. Rumack

    Acetaminophen misconceptions

    Hepatology

    (2004)
  • G.P. Bray et al.

    Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure

    Hum Exp Toxicol

    (1992)
  • Cited by (0)

    Conflict of Interest: The authors have nothing to disclose.

    View full text